Keith Graham

This inventor holds 15 USPTO granted patents and 29 published patent applications, plus 1 CIPO patent and 11 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Bayer Pharma Aktiengesellschaft, Piramal Imaging Sa, Bayer Aktiengesellschaft. Active years: 2013-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Keith Graham. Retrieved from https://idiyas.com/inventor/keith-graham

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 15 (Patent Applications = 29)

% Patents Active = 33.3

CIPO Patents = 1 (Patent Applications = 4)

EPO Patents = 11 (Patent Applications = 41)

Average Co-Inventor Count = 7.5

ph-index = 2

Forward Citations = 17(Granted Patents)

Company Filing History:

9 out of 387

Bayer Pharma Aktiengesellschaft

Bayer Aktiengesellschaft

patents

4. 2 out of 490

The Broad Institute, Inc.

patents

5. 1 out of 1,272

Dana-Farber-Cancer Institute Inc.

patents

where one patent can have more than one assignee

Years Active: 2013-2026

Loading Chart...

Areas of Expertise:

Phosphorus Derivatives

SOS1 Inhibitors

Pyrazolopyridinamines

Radiolabeled Amino Acids

Thiazolopyrimidines

Chromatography

4H-Pyrrolo Compounds

MKNK1 Inhibitors

Diagnostic Imaging

Heterocyclic Compounds

Amino Acid Derivatives

15 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12760047 - Phosphorus derivatives as SOS1 inhibitors (2026-10-13),

2. 12679836 - 4H-PYRROLO[3,2-C]PYRIDIN-4-ONE COMPOUNDS (2026-07-14),

3. 11339157 - 4H-pyrrolo[3,2-c]pyridin-4-one derivatives (2022-05-24),

4. 10487092 - Pyrazolopyridinamines as MKNK1 and MKNK2 inhibitors (2019-11-26),

5. 10428063 - 4H-pyrrolo[3,2-C]pyridin-4-one derivatives (2019-10-01),

6. 10428044 - 3-amino-1,5,6,7-tetrahydro-4H-indol-4-ones (2019-10-01),

7. 10308629 - 1H-pyrrol-3-amines (2019-06-04),

8. 10227299 - 3-amino-1,5,6,7-tetrahydro-4H-indol-4-ones (2019-03-12),

9. 9675612 - Substituted thiazolopyrimidines (2017-06-13),

10. 9540392 - Thienopyrimidines (2017-01-10),

11. 9375497 - [F-18]-labeled L-glutamic acid, [F-18]-labeled L-glutamine, derivatives thereof and use thereof and processes for their preparation (2016-06-28),

12. 9308282 - [F-18]-labelled L-glutamic acid and L-glutamine derivatives (I), their use and processes for their preparation (2016-04-12),

13. 9238631 - Radiolabeled amino acids for diagnostic imaging (2016-01-19),

14. 8968701 - Usage of low to medium-pressure liquid chromatography for the purification of radiotracers (2015-03-03),

15. 8557776 - [object Object] (2013-10-15),

Title: Inventor Keith Graham: Pioneering Pharmaceutical Innovations in Berlin

Introduction

Keith Graham, a renowned inventor based in Berlin, Germany, holds an impressive portfolio of 13 patents. His significant contributions to the field of pharmaceuticals have garnered attention and respect in the scientific community.

Latest Patents

Graham's latest innovations include novel derivatives of 4H-pyrrolo[3,2-c]pyridin-4-one. He has developed processes for creating these compounds and outlined their potential use as pharmaceuticals. Another noteworthy invention is centered around pyrazolopyridinamines which serve as inhibitors for MKNK1 and MKNK2. This invention details substituted pyrazolopyridinamine compounds that can be utilized in treating various diseases, particularly those relating to hyperproliferative disorders, inflammation, and associated pain.

Career Highlights

Throughout his career, Keith Graham has been associated with esteemed companies such as Bayer Pharma Aktiengesellschaft and Piramal Imaging. His innovative work in these organizations has led to a deeper understanding of pharmaceutical compounds and their applications in medical treatment.

Collaborations

Graham has collaborated with notable colleagues in the industry, including Ulrich Klar and Philip Lienau. These partnerships have been essential in advancing his research and contributing to the success of his inventions.

Conclusion

Keith Graham continues to impact the pharmaceutical industry through his groundbreaking inventions and active collaboration with fellow scientists. His dedication to innovation positions him as a prominent figure in the realm of pharmaceutical research, providing new solutions to complex medical challenges.

Profile summary based on public USPTO records.